Clinicopathologic characteristics of sample sets
| Clinicopathologic parameter . | Training set, n = 65 . | Test set, n = 72 . |
|---|---|---|
| Sex, no. (%) | ||
| Male | 28 (43) | 27/72 (38) |
| Female | 37 (57) | 45/72 (63) |
| Age,* y [median (range)] | 43 (16-60) | 49 (27-60) |
| WBC,† ×1000/μL [median (range)] | 31 (0.5-238) | 14 (0.8-156) |
| LDH,* U/L [median (range)] | 553 (139-6676) | 454 (133-1941) |
| Preceding malignancy | 0/60 | 1/66 |
| FAB n/N (%) | ||
| M0 | 6/64 (9) | 5/65 (8) |
| M1 | 17/64 (27) | 11/65 (17) |
| M2 | 15/64 (23) | 21/65 (32) |
| M4 | 16/64 (25) | 17/65 (26) |
| M5 | 10/64 (16) | 9/65 (14) |
| M6 | 0/64 (0) | 2/65 (3) |
| FLT3-ITD mutation n/N (%) | 28/64 (44) | 22/63 (35) |
| FLT3-TKD mutation‡ n/N (%) | 14/64 (22) | 3/63 (5) |
| MLL-PTD mutation, n/N (%) | 4/65 (6) | 5/65 (8) |
| CEBPA mutation n/N (%) | 6/56 (11) | 10/60 (17) |
| NPM1 mutation n/N (%) | 34/61 (56) | 32/60 (53) |
| Median follow-up,§ d | ||
| All patients | 405 | 515 |
| Survivors‖ | 1360 | 785 |
| Median survival time,§ d | 405 | 675 |
| Median remission duration,§ d | 920 | 615 |
| Clinicopathologic parameter . | Training set, n = 65 . | Test set, n = 72 . |
|---|---|---|
| Sex, no. (%) | ||
| Male | 28 (43) | 27/72 (38) |
| Female | 37 (57) | 45/72 (63) |
| Age,* y [median (range)] | 43 (16-60) | 49 (27-60) |
| WBC,† ×1000/μL [median (range)] | 31 (0.5-238) | 14 (0.8-156) |
| LDH,* U/L [median (range)] | 553 (139-6676) | 454 (133-1941) |
| Preceding malignancy | 0/60 | 1/66 |
| FAB n/N (%) | ||
| M0 | 6/64 (9) | 5/65 (8) |
| M1 | 17/64 (27) | 11/65 (17) |
| M2 | 15/64 (23) | 21/65 (32) |
| M4 | 16/64 (25) | 17/65 (26) |
| M5 | 10/64 (16) | 9/65 (14) |
| M6 | 0/64 (0) | 2/65 (3) |
| FLT3-ITD mutation n/N (%) | 28/64 (44) | 22/63 (35) |
| FLT3-TKD mutation‡ n/N (%) | 14/64 (22) | 3/63 (5) |
| MLL-PTD mutation, n/N (%) | 4/65 (6) | 5/65 (8) |
| CEBPA mutation n/N (%) | 6/56 (11) | 10/60 (17) |
| NPM1 mutation n/N (%) | 34/61 (56) | 32/60 (53) |
| Median follow-up,§ d | ||
| All patients | 405 | 515 |
| Survivors‖ | 1360 | 785 |
| Median survival time,§ d | 405 | 675 |
| Median remission duration,§ d | 920 | 615 |